ONE KENDALL SQUARE. BUILDING 600-700, CAMBRIDGE, MA
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Announces Oversubscribed $85 Million Private Placement
Investor Presentation
Korro Bio, Inc. Amends Employment Agreement for Jeffrey Cerio
Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs
News, Material Contracts
Reports Second Quarter 2025 Financial Results and Provides Business Updates
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Submission Upload
Correspondence
Post-Effective Amendment to Registration Statement